Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy

Table 3 A comparison of the clinical characteristics of 78 patients with primary sclerosing cholangitis and ulcerative colitis who underwent colectomy categorized by the presence or absence of primary endpoints

Clinical characteristics1	Without primary endpoints (n = 52)	With primary endpoints (n = 26)	P value2
Gender, %female	11 (21)	11 (42)	0.052
Age at colectomy (yr)	38.7 (27.8, 51.6)	45.8 (29.4, 52)	0.40
Presence of advanced liver fibrosis	12 (23)	12 (46)	0.032
Pre-operative Mayo risk score	-0.1 (-0.9, 0.9)	1.3 (-0.2, 2.2)	0.012
Pre-operative MELD score	7 (6, 9)	14 (11, 18)	< 0.0012
History of anemia or blood loss requiring a post-operative blood transfusion within 1 mo	4 (7.7)	7 (27)	0.022
Post-operative liver complications within 1 mo	3 (5.8)	6 (23)	0.022
Length of hospital stay (d)	7 (5, 10)	9 (7, 15)	0.07
Hemoglobin (g/dL)	13.1 (11.9, 14.4)	10.8 (9.8, 13.1)	< 0.0012
Platelet count (× 109/L)	296 (247, 357)	244 (126, 337)	0.022
INR	0.9 (0.9, 1.0)	1.1 (1.1, 1.3)	< 0.0012
Total bilirubin (mg/dL)	0.7 (0.5, 1.3)	2.3 (0.6, 5.0)	0.0012
Direct bilirubin (mg/dL)	0.2 (0.1, 0.4)	0.9 (0.2, 3.5)	0.0022
ALP (U/L)	352 (180, 494)	709 (276, 1232)	0.0032
AST (U/L)	44 (31, 90)	80 (36, 129)	0.09
Albumin (g/dL)	4.1 (3.4, 4.3)	3.5 (3.3, 3.9)	< 0.0012
Duration of follow up from colectomy to the last follow-up (yr)	5.5 (3.8, 8.8)	2.6 (0.8, 5.6)	0.0072

¹Median [interquartile range (IQR)] or n (%);

²P value < 0.05 for primary sclerosing cholangitis patients with or without primary endpoints and those variables with a P value < 0.1 in a univariate analysis were included in the multivariate analysis. AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; MELD: Model for End-Stage Liver Disease.